A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia (CHAMP)
Sponsor: Nevakar, LLC
Principal Investigator: Melanie Schmitt, MD
Study Coordinator: Angie Adler
In stage 1, the purpose of this study is to evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period. In stage 2, the purpose of the study is to observe safety and efficacy in subjects re-randomized to one (1) year of treatment with NVK-002 or Vehicle following 3 years of treatment in children with progressive myopia.
This will be a 3-arm randomized, multi-center, double-masked, placebo-controlled study conducted in 2 stages.
Treatment arms are:
NVK-002 low dose concentration
NVK-002 high dose concentration
Diagnosis and Key Eligibility Criteria:
Children aged 3-10 years with myopia spherical equivalent of at least -0.50 diopters and no greater than -6.00 diopters in each eye as measured by cycloplegic autorefraction.
Duration of Study: 4 years
For more information, contact Angie Adler 608-265-7557